Colloidal Oatmeal Research Articles

52272 Ceramide profiling of atopic dermatitis and effects of an eczema calming lotion containing petroleum jelly, fatty acids and colloidal oatmeal.

52272 Ceramide profiling of atopic dermatitis and effects of an eczema calming lotion containing petroleum jelly, fatty acids and colloidal oatmeal.

53925 Ultrastructural characterization of the stratum corneum from atopic dermatitis and the effects of an eczema calming lotion containing petroleum jelly, fatty acids and colloidal oatmeal

53925 Ultrastructural characterization of the stratum corneum from atopic dermatitis and the effects of an eczema calming lotion containing petroleum jelly, fatty acids and colloidal oatmeal

50577 Benefits of a Colloidal Oatmeal Cream with Biomimetic Lipid Combination and Beta Glucan Active in Atopic Dermatitis in Brazilian Multi-Ethnic Patients: Instrumental, Clinical, Microbiome, Images, and Patient-Perception

50577 Benefits of a Colloidal Oatmeal Cream with Biomimetic Lipid Combination and Beta Glucan Active in Atopic Dermatitis in Brazilian Multi-Ethnic Patients: Instrumental, Clinical, Microbiome, Images, and Patient-Perception

Dihydroavenanthramide D Enhances Skin Barrier Function through Upregulation of Epidermal Tight Junction Expression.

Skin barrier dysfunction and thin epidermis are hallmarks of sensitive skin and contribute to premature aging. Avenanthramides are the primary bioactive components of colloidal oatmeal, a commonly used treatment to enhance skin barrier function. This study investigated the relationship between skin barrier function and epidermal characteristics and explored the potential of dihydroavenanthramide D (dhAvD), a synthetic avenanthramide, to improve the skin barrier. We observed a significant correlation between impaired skin barrier function and decreased epidermal thickness, suggesting that a weakened barrier contributes to increased sensitivity. Our in vitro results in HaCaT cells demonstrated that dhAvD enhances keratinocyte proliferation, migration, and tight junction protein expression, thereby strengthening the skin barrier. To mimic skin barrier dysfunction, we treated keratinocytes and full-thickness skin equivalents with IL-4 and IL-13, cytokines that are implicated in atopic dermatitis, and confirmed the downregulation of tight junction and differentiation markers. Furthermore, dhAvD treatment restored the barrier function and normalized the expression of key epidermal components, such as tight junction proteins and natural moisturizing factors, in keratinocytes treated with inflammatory cytokines. In the reconstructed human skin model, dhAvD promoted both epidermal and dermal restoration. These findings suggest that dhAvD has the potential to alleviate skin sensitivity and improve skin barrier function.

Effects of eczema calming lotion on the stratum corneum in atopic dermatitis: Corneodesmosin and intercellular lipid lamellae.

Atopic dermatitis (AD) is characterized by compositional and structural changes to the skin at lesional sites. Alteration to the levels and organization of both protein and lipid components are associated with disease status and lead to impaired barrier and hydration. Corneodesmosin (CDSN) and the arrangement and length of the intercellular lipid lamellae (ICLL) are altered in disrupted skin states. The aim of this research was to profile the distribution of CDSN and the ICLL in the stratum corneum (SC) at lesional and non-lesional sites in AD-prone skin and to investigate the impact of an eczema calming lotion containing petroleum jelly, fatty acids, and colloidal oatmeal. An IRB-approved study was conducted with participants with active AD. From a small subset of participants, tape strips were collected from lesional and non-lesional sites on the arm, prior to and after twice daily application, over 4 weeks of an eczema calming lotion containing petroleum jelly, fatty acids, and colloidal oatmeal. Fluorescent antibody staining was used to investigate the distribution of CDSN. Transmission electron microscopy (TEM) was used to characterize the ICLL. The distribution/coverage of CDSN was similar between lesional and non-lesional sites at baseline; application of the lotion resulted in a more defined honeycomb/peripheral distribution. Normalized ICLL (nICLL) was lower in baseline samples from lesional sites relative to non-lesional sites. Application of the lotion increased this parameter by the end of the study at all sites. The eczema calming lotion containing petroleum jelly, fatty acids and colloidal oatmeal provided changes in corneodesmosomal proteins distribution and ICLL, consistent with improvements in corneocyte maturation and improved barrier function in the skin of individuals with atopic dermatitis.

Itch-Relieving Cosmetics

This review aims to explore the evolving role of cosmetics in alleviating itch, transcending their traditional aesthetic function. With a focus on formulations enriched with natural oils and other bioactive components, we examine the efficacy and safety of various cosmetic ingredients designed to control itch. Highlighted are ingredients such as colloidal oatmeal, postbiotics, menthol, peppermint, cryosim-1, capsaicin, asivatrep, polidocanol, pramoxine hydrocholoride, and palmitoylethanolamide, which are recognized to reduce itch. Special attention is also given to phytochemicals that can modulate the Janus kinase/signal transducer and activator of transcription signaling pathway and carry the potential as an itch-relieving cosmetic ingredient. This review encompasses clinical studies that verify the itch relieving effect of these cosmetic ingredients. By integrating current scientific evidence, we aim to shed light on the potential of anti-itch cosmetics as an adjunct to standard itch treatment, thereby broadening our understanding of their role in dermatological care.

Prospective Randomized Double-Blind Vehicle-Controlled Study of Topical Coconut and Sunflower Seed Oil-Derived Isosorbide Diesters on Atopic Dermatitis.

Background: Preliminary studies support the use of topical coconut and sunflower seed oil for atopic dermatitis (AD). However, standardized topical formulations of fatty acids from these sources have not been studied. Objective: This study investigates whether coconut oil- and sunflower seed oil-derived isosorbide diesters can be used in conjunction with colloidal oatmeal to improve itch, AD severity, and the need for topical steroids in adults. Methods: This was a single-center, 4-week, randomized, double-blind, and vehicle-controlled study conducted between 2021 and 2022. Thirty-two male and female adults with mild-to-moderate AD were enrolled and completed the study. Participants were randomized to receive either 0.1% colloidal oatmeal (vehicle) or isosorbide diesters (IDEAS, 4% isosorbide dicaprylate and 4% isosorbide disunflowerseedate) along with 0.1% colloidal oatmeal. The main outcomes of the study were changes in the visual analogue rating of itch and 75% improvement in the Eczema Area and Severity Index score (EASI 75) at 4 weeks. Other measures included the use of topical steroids and the relative abundance of skin Staphylococcus aureus. Results: Participants in the IDEAS group had a 65.6% improvement in itch compared with 43.8% in the vehicle group (P = 0.013). In total, 56.5% and 25% of the those in the IDEAS and vehicle groups, respectively, achieved EASI 75 at 4 weeks (P = 0.07). There was no difference in skin hydration or transepidermal water loss. The relative abundance of S. aureus was decreased in the IDEAS group at week 4 compared with no change in the vehicle group (P = 0.044). Topical corticosteroid use increased in the vehicle group compared with a decrease in the IDEAS group at week 1 (292.5% vs 24.8%; P value = 0.039) and week 2 (220% vs 46%; P value = 0.08). Conclusions: Topical application of emollients containing coconut oil- and sunflower seed oil-derived fatty esters may improve itch, reduce topical steroid use, and reduce the relative abundance of S. aureus in mild-to-moderate AD. CTR number: NCT04831892.

Cetyl alcohol, stearyl alcohol and colloidal oatmeal-based gentle skin cleanser in management of dry and sensitive skin: a cross-sectional study

Background: Effective skin cleansing is vital for maintaining skin health and appearance. An ideal skin cleaner retains moisture, removes oils, sweat, and dirt without causing irritation or dehydration. This study was designed to evaluate the efficacy, safety, tolerability and usage trends of a gentle skin cleanser containing cetyl alcohol, stearyl alcohol and colloidal oatmeal for individuals having dry and sensitive skin. Methods: We conducted a retrospective review at 102 centres, focusing on individuals aged 18 to 65 years with atopic dermatitis and dry skin conditions who required the use of gentle skin cleanser. Total 568 cases were taken; 488 cases of dry and sensitive skin were further analysed over a 2-week study period. Results: Gentle skin cleanser exhibited significant reduction (p<0.0001) in skin dryness, itchiness and irritation by 4.42±1.92 (63.38%), 4.03±2.71 (49.38%) and 4.44±2.07 (65.58%) respectively in participants with dry skin and by 4.25±1.48 (58.49%), 3.26±3.22 (18.02%) and 4.42±1.56 (63.23%) in participants with sensitive skin after its regular usage. Participants provided positive feedback and expressed overall satisfaction with the study product. Conclusions: Skin cleanser was efficacious and well-tolerable in participants in providing moisturizing, soothing, exfoliating, and antioxidant effects making it a preferred primary choice for managing dry and sensitive skin. The cleanser effectively cleansed excess oil, dirt, dead cells, microorganisms, and sweat providing a gentle and mild experience, in daily skin care.

The effect of different formulations with colloidal oatmeal on the epidermal barrier function and hydration

The effect of different formulations with colloidal oatmeal on the epidermal barrier function and hydration

A MECHANISTIC INSIGHT OF NATURAL PRODUCTS FOR ECZEMA TREATMENT (PART I)

Eczema is termed as a chronic relapsing atopic dermatitis which is a chronic, inflammatory dermatosis mediated by immune system and is characterized by T- helper 2 immune response phenotype. Eczema is associated with disturbance in sleep and it also affects the quality of life. Emollient, antimicrobial agents, corticosteroid or immune-modulating agents are used for treatment of eczema. Pathogenesis of eczema involves complex interactions between susceptible genes, immunological factor, and defects in skin barriers, neuro-endocrine factors and factors related to environment like change in weather, food and aeroallergens. Because there is no cure till date for eczema, Chinese medicines which are part of dietary therapies are being adopted by the Asian patients. In the treatment of skin disorders and wounds a tremendous role has been played by Herbal extracts and isolated plant compounds. Recently a lot of new herbal drugs have been developed that were tested in controlled clinical or preclinical studies. St. John’s wort, licorice, tormentil, bitter substances, evening primrose and many more biomedicines, topical agents: coconut oil, colloidal oatmeal, sunflower oil, mustard oil, glycerin, and oral Chinese herbal therapy are used to treat AD. Probiotics, and vitamins are also used as oral agents in treatment of AD and all these bioagents have shown good results in treatment of atopic dermatitis. Wind, dampness and heat are the three main pathogenic factors of eczema. Various Chinese herb such as cortex moutan radix (danpi), radix paeoniae alba (bai shao), potentilla chinensis ser (weilingcai) and radix glycyrrhizae (gan cao) are common treatments for eczema allergy. It is being indicated in pharmacological studies that these herbs have anti-allergic, anti- inflammatory and sedative action for itchiness . These studied medicinal plants were found to be effective in eczema therapy, further mechanistic and clinical studies are required to establish this claim.

18724 Tolerance and subject satisfaction of an over the counter colloidal oatmeal (Avena sativa) lotion in patients with psoriasis and sensitive skin

Psoriasis is an autoimmune skin disease that is associated with significant impairment in quality of life including skin discomfort and dissatisfaction of skin appearance. The purpose of this study was to determine the tolerability and satisfaction in skin appearance of a 1% colloidal oatmeal lotion on individuals with psoriasis. Sixty women with psoriasis and self-reported sensitive skin were enrolled into the study. Subjects applied only the assigned 1% colloidal oatmeal lotion to their entire body at least once per day for 4 weeks. Subjects assessed their skin condition on a 100-point VAS and completed product-satisfaction and Quality of life questionnaires at baseline and after 4 weeks of use. After 4 weeks of application, subjects perceived a significant improvement in each of the skin parameters queried including dryness, desquamation, roughness, smoothness, softness, suppleness, redness, discomfort, and itching with an average of 38% improvement over all the parameters. The greatest improvements included itch and desquamation with a 45% improvement over baseline scores for both. More than 96% of subjects thought the product helped to reduce both the severity and number of patches on the body. In addition, 100% of subjects felt the product was suitable to use daily for their skin type. The product was well tolerated and no product related skin adverse events were reported during the study. In conclusion, the over-the-counter colloidal oatmeal moisturizing lotion improves the skin appearance and discomfort associated with psoriasis and is a suitable adjunctive moisturizer for daily skincare in this patient population.

Compatibility of a Colloidal Oatmeal Containing Body Wash for Pediatric Subjects with Atopic Dermatitis

Abstract not available.

Efficacy of Nonprescription Moisturizers for Atopic Dermatitis: An Updated Review of Clinical Evidence.

Twice-daily moisturization is recommended by international guidelines as the bedrock of the management of atopic dermatitis (AD). Moisturizers should be selected based on proven clinical effectiveness in improving the skin barrier and improving the symptoms of AD. We searched the PubMed database for clinical trials assessing daily moisturization for the treatment of AD published between 2006 and 2019. Studies had to assess the efficacy of commercially available moisturizers using objective measures of corneometry, transepidermal water loss, or incidence of flare as endpoints, and treatments had to be currently available to patients. Clinical studies showed that moisturization (typically twice daily) significantly improved the skin barrier in adults and children with AD. Longer-term flare studies showed that daily moisturization reduced the incidence of flares and extended the time between flares. Proactive moisturization of infants at high risk of developing AD may reduce its manifestation. Therapeutic moisturizers for AD are specifically formulated with ingredients that target symptoms of AD, such as itch, inflammation, or compromised skin barrier. The US FDA requires that any moisturizer available in the USA and claiming to treat AD must contain colloidal oatmeal. Healthcare providers can maximize compliance and outcomes by educating patients on the benefits of liberally applying a therapeutic moisturizer twice daily to support the skin barrier and help reduce the incidence of flares. Specific recommendations should be for clinically tested moisturizers evaluated using objective, validated skin assessments.

Novel yeast extract is superior to colloidal oatmeal in providing rapid itch relief.

Approximately, 13.5% of the population suffers from chronic itch. Many cosmetic and pharmaceutical treatments for itch are available; however, cosmetic treatments are not reliably effective and most pharmaceutical formulations carry the risk of adverse events with chronic use. Previously, we have reported a novel extraction process of Saccharomyces cerevisiae, that is, Baker's yeast. The extract obtained from the novel process demonstrates superior anti-itch properties compared to other yeast extracts. In our previous study, we demonstrated that, after 30 minutes, the extract significantly reduced itch when compared to a placebo lotion (P=.002). In the present study we conducted a head-to-head comparison with the leading cosmetic itch product: lotion containing colloidal oatmeal (CO). A randomized double-blinded study of 60 patients was conducted. In our study, the novel yeast extract was vastly superior to the CO containing lotion (Aveeno™ Eczema Therapy Moisturizing Cream). We saw statistically significant difference in the reduction of itch (P=.0001) using the novel yeast extract vs the CO lotion. Additionally, the yeast extract was shown to relieve itch in as little as one minute after application. The novel yeast extract rapidly relieves itch and is superior to the cosmetic market leader, CO lotion.

The Efficacy of Colloidal Oatmeal Cream 1% as Add-on Therapy in the Management of Chronic Irritant Hand Eczema: A Double-Blind Study.

BackgroundIrritant contact dermatitis (ICD) is the most frequent cause of hand eczema (HE). There is promising evidence with the use of topical oatmeal compounds in the management of inflammation- and itch-responses associated with diverse dermatologic conditions. This study aimed to evaluate the clinical benefit of colloidal oatmeal cream in the management of chronic irritant HE.MethodsFrom October 2018 to November 2019, 79 patients with diagnosis of chronic irritant HE were allocated into either intervention or control groups by block randomization method. Besides fluocinolone 0.025% ointment for the first 2 weeks of treatment period, patients in the intervention and control groups were asked to use colloidal oatmeal 1% cream or base cream for additional 4 weeks as monotherapy. Changes in the HE severity based on the hand eczema severity index (HESCI) score, pruritus severity based on the visual analogue scale (VAS), and impact of skin disorder on patients quality of life based on the Dermatology Life Quality Index (DLQI) from baseline to weeks 2, 4, and 6 were assessed in the study groups.ResultsFifty subjects, 26 in intervention and 24 in control, completed the course of the study. The results indicated, though relatively comparable decrease in mean HESI and VAS scores was observed in both groups by the end of week 2, thereafter until end of the study a non-return of symptoms to baseline conditions was observed in the intervention group, while there was a significant return of symptoms to baseline conditions in the control group (p value<0.001 in both conditions). Further, a noticeable improvement in the DLQI score was seen in the intervention group compared with the control group (p value<0.001).ConclusionFindings demonstrate that colloidal oatmeal, a natural product with proven barrier protection, moisturization, anti-inflammatory, and soothing properties, can have ameliorative effects on eczema severity symptoms in patients with chronic irritant HE.

Cost and effectiveness of prescribing emollient therapy for atopic eczema in UK primary care in children and adults: a large retrospective analysis of the Clinical Practice Research Datalink

BackgroundThe Clinical Practice Research Datalink (CPRD) was used to evaluate the overall costs to the National Health Service, including healthcare utilisation, of prescribing emollients in UK primary care for dry skin and atopic eczema (DS&E).MethodsPrimary care patients in the UK were identified using the CPRD and their records were interrogated for the 2 years following first diagnosis of DS&E. Data from patients with (n = 45,218) and without emollient prescriptions (n = 9780) were evaluated. Multivariate regression models were used to compare healthcare utilisation and cost in the two matched groups (age, sex, diagnosis). Two sub-analyses of the Emollient group were performed between matched groups receiving (1) a colloidal oatmeal emollient (Aveeno-First) versus non-colloidal oatmeal emollients (Aveeno-Never) and (2) Aveeno prescribed first-line (Aveeno-First) versus prescribed Aveeno later (Aveeno-Subsequently). Logistic regression models calculated the odds of prescription with either potent / very potent topical corticosteroids (TCS) or skin-related antimicrobials.ResultsCosts per patient were £125.80 in Emollient (n = 7846) versus £128.13 in Non-Emollient (n = 7846) matched groups (p = 0.08). The Emollient group had fewer visits/patient (2.44 vs. 2.66; p < 0.0001) and lower mean per-visit costs (£104.15 vs. £113.25; p < 0.0001), compared with the Non-Emollient group. Non-Emollient patients had 18% greater odds of being prescribed TCS and 13% greater odds of being prescribed an antimicrobial than Emollient patients. In the Aveeno-First (n = 1943) versus Aveeno-Never (n = 1943) sub-analysis, costs per patient were lower in the Aveeno-First compared with the Aveeno-Never groups (£133.46 vs. £141.11; p = 0.0069). The Aveeno-Never group had ≥21% greater odds of being prescribed TCS or antimicrobial than the Aveeno-First group. In the Aveeno-First (n = 1357) versus Aveeno-Subsequently (n = 1357) sub-analysis, total costs were lower in the Aveeno-First group (£140.35 vs. £206.43; p < 0.001). Patients in the Aveeno-Subsequently group had 91% greater odds of being prescribed TCS and 75% greater odds of being prescribed an antimicrobial than the Aveeno-First group.ConclusionsAcknowledging limitations from unknown disease severity in the CRPD, the prescription of emollients to treat DS&E was associated with fewer primary care visits, reduced healthcare utilisation and reduced cost. Prescribing emollients, especially those containing colloidal oatmeal, was associated with fewer TCS and antimicrobial prescriptions.Trial registrationThe study is registered at http://isrctn.com/ISRCTN91126037.

Fermentation of colloidal oatmeal by cutaneous bacteria results in enhanced production of lactic acid and short-chain fatty acids

Fermentation of colloidal oatmeal by cutaneous bacteria results in enhanced production of lactic acid and short-chain fatty acids

999 Prebiotic colloidal oatmeal supports the growth of S. epidermidis and enhances the production of lactic acid

999 Prebiotic colloidal oatmeal supports the growth of S. epidermidis and enhances the production of lactic acid

Selected active naturals for atopic dermatitis: Atopic Dermatitis Part 1

The desire for naturally derived agents is a growing trend for patients, physicians, and pharmaceutical companies. Studies indicate that complementary and alternative medicine is often used by patients and parents of children with atopic dermatitis, not necessarily with beneficial results. A half-dozen natural agents (ie, topical agents: coconut oil, colloidal oatmeal, sunflower oil, mustard oil, glycerin, and oral Chinese herbal therapy) are discussed because they have become popular for their expected activity in the therapy of atopic dermatitis. A critical review of the published literature on these agents is presented with specific focus on potential such side effects as hepatotoxicity with Chinese herbals.

Colloidal oatmeal emollient as an alternative skincare approach in radiotherapy: a feasibility study

AbstractAimTo assess the feasibility of a randomised controlled trial (RCT) on patients receiving radical radiotherapy for carcinoma of the anus in order to compare the present skincare advice at the time of the study with an alternative product, Aveeno, used primarily for dermatological and chemotherapeutic-induced skin conditions.Materials and methodStandardised Radiation Therapy Oncology Group (RTOG) grading and skincare assessments were used primarily to inform on physical reactions within a RCT. A pre-existing morbidity/quality-of-life instrument ‘the Head and Neck Radiotherapy Questionnaire’, which was validated for use with radiotherapy patients in preceding studies, was adapted for anus patients and formed the secondary basis for data collection. In all, 24 participants undergoing radical radiotherapy for anal cancer were randomised into two arms, Aveeno cream versus Aqueous Cream BP, and reviewed weekly to collect data and perform analysis and Mann–Whitney U non-parametric statistical tests.ResultsRTOG gradings for skin reactions were comparable week by week across the cohorts, with a baseline 100% of participants exhibiting RTOG 0 at week 1 in all areas, through to week 6 where both cohorts had progressed to higher RTOG grades. The Aveeno cohort, however, indicated ap-value approaching significance in regards to epidermal regeneration at follow-up 1 (p=0·0543). Questionnaires yielded diminishing responses as treatment progressed correlating with advancing RTOG grades, and exhibited increasing negativity in responses in correlation with advancing RTOG grade exhibited.ConclusionThe study was the first to recognise colloidal oatmeal as a skincare approach in the radiotherapy setting and recognises the potential benefits of Aveeno in radiation-induced skin reactions. The study determined the RTOG grading system to be robust as a method of evaluation of skin reactions and the questionnaires deemed the quality-of-life assessment to be a necessity in order to address patients’ psychological needs in addition to the physical needs.